AstraZeneca slips after Imfinzi falls short in cancer trial
By Geoffrey Smith Investing.com -- AstraZeneca (LON:AZN) stock slipped in morning trading in London on Monday, after the U.K.-Swedish pharma company said its Imfinzi drug had failed to...
-
-
AstraZeneca acquires biotech Neogene for $320M in bid to expand cancer treatments
By Scott Kanowsky Investing.com -- AstraZeneca PLC (LON:AZN) has signed a $320 million cash and debt deal to acquire bio-technology group Neogene Therapeutics, as the U.K. drugmaker looks...
-
AstraZeneca raises 2022 earnings outlook after Q3 results beat estimates
By Scott Kanowsky Investing.com -- AstraZeneca PLC (LON:AZN) has raised its guidance for full-year income per share, citing strong returns in its third quarter, but warned that the outlook...
-
European Stocks Edge Higher; Weak Chinese Data Hits Sentiment
By Peter Nurse Investing.com - European stock markets largely edged higher Monday, starting the new week on a cautious note as investors digested weak Chinese economic data. By 04:15 ET...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
